MD Anderson Cancer Center and Yingli Pharma US Inc. entered a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.
The five-year collaboration aims to drive existing Yingli therapeutic candidates into four U.S.-based clinical trials and to facilitate preclinical discovery and development in additional indications.
Two of the programs supported by the collaboration will leverage favorable clinical trial findings collected from China-based studies.
The first program will focus on linperlisib, a PI3Kδ inhibitor with a novel structure, which has had positive results in eight active or completed phase I and phase II clinical trials for patients with lymphomas and solid tumors, including peripheral T cell lymphoma.
The second program will develop YL-13027, a novel, oral TGFβR1 inhibitor for use in advanced solid tumors with plans to initiate a U.S.-based phase I clinical trial in 2022, led by Jordi Rodon, associate professor of Investigational Cancer Therapeutics at MD Anderson.
In addition to advancing existing clinical programs, the collaboration also will focus on translational studies to further Yingli’s discovery programs. The partnership will provide a steady stream of new therapeutic candidates for oncology clinical development, which the MD Anderson team, including David S. Hong, deputy chair of Investigational Cancer Therapeutics, will investigate.
